In The Press2017-10-18T01:32:10+00:00
2505, 2021

Phyton Biotech has received Regulatory Approval from China’s NMPA for its plant cell fermentation-derived Paclitaxel Active Pharmaceutical Ingredient.

May 25th, 2021|

Phyton Biotech is pleased to announce approval from China’s regulatory body – National Medical Products Administration (NMPA) - for Phyton’s Drug Master File for paclitaxel active pharmaceutical ingredient produced via plant cell fermentation (PCF®).

1101, 2021

Phyton Biotech Announces the Successful Establishment of Plant Cell Lines to Source Key Building Block for Treatment of Rare Dermatologic Conditions

January 11th, 2021|

Phyton Biotech’s Plant Cell Fermentation (PCF) technology has been successfully used to develop high-yielding plant cell lines of the source of cyclopamine, a key raw material for PellePharm’s patedigib topical gel.

Go to Top